Three-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution

FEBS Lett. 1993 May 24;323(1-2):68-72. doi: 10.1016/0014-5793(93)81450-e.

Abstract

A point mutation (Ala-589 to Thr) in the transmembrane protein of the human immunodeficiency virus type 1 (HIV-1) has been shown to decrease the sensitivity of the virus to the neutralizing effect of human HIV-1 specific antibodies [(1990) J. Virol. 64, 3240-3248]. Here 17-residue peptides with the parental and mutant sequences were compared: the parental peptide bound antibodies of sera from HIV-1 infected persons more frequently and with higher affinity than the mutant peptide. However, according to circular dichroism (CD), NMR spectroscopy and molecular modelling the peptides have indistinguishable backbone conformations under a variety of experimental conditions. These techniques showed for both peptides that no ordered helix was present in water solution. However, for both peptides in alcohol-water solutions approximately 60% alpha-helix could be induced. The three-dimensional structures of these peptides provide a basis for understanding how this mutation in the transmembrane protein may affect the interaction with both the outer envelope glycoprotein and with antibodies.

MeSH terms

  • Amino Acid Sequence
  • Circular Dichroism
  • Computer Simulation
  • Gene Products, env / chemistry*
  • Gene Products, env / immunology
  • HIV Antibodies / chemistry
  • HIV Antibodies / immunology
  • HIV Infections / immunology
  • HIV-1 / chemistry*
  • HIV-1 / immunology
  • Humans
  • Immunohistochemistry
  • Magnetic Resonance Spectroscopy
  • Models, Molecular
  • Molecular Sequence Data
  • Neutralization Tests
  • Peptide Fragments / chemistry*
  • Peptide Fragments / immunology
  • env Gene Products, Human Immunodeficiency Virus

Substances

  • Gene Products, env
  • HIV Antibodies
  • HIV-env (583-599) peptide
  • Peptide Fragments
  • env Gene Products, Human Immunodeficiency Virus